Investor Presentation - First Six Months of 2021
10
Investor presentation First six months of 2021
RybelsusⓇ TRX volume is growing despite two commercial
lockdowns in the US
RybelsusⓇ uptake in the US1 since launch
In H1 2021, RybelsusⓇ sales were DKK 1,674 million
RybelsusⓇ has now been launched in 18 countries
NBRx count
(000s)
NBRX
TRX (RHS)
Restricted field force
TRX count
Partial re-entry
(000s)
Full re-entry
40
8
Mid-May
35
In the US:
Mid-Feb
•
30
6
Early-Jun
End-Nov
25
4
Mid-Mar
22
20
•
.
.
Increasing breadth and awareness amongst HCPS
More than 80% of new prescriptions are new to the GLP-1 class
Full field force re-entry middle of May 2021
Direct-to-consumer advertising continues
Outside of the US:
In Japan, RybelsusⓇ has reached a 0.7% modern oral antidiabetics
(MOAD) value market
15
2
10
5
0
0
1
11
21
31
41
51
61
71
81
90
2019
Time since launch (weeks)
2020
2021
1 RybelsusⓇ is based on Oct 2019 focus launch. Each data points represents a rolling four-week average.
Note: NBRX: New-to-brand prescriptions, F2F: Face-to-face; RHS: Right hand side axis; HCP: Healthcare Professional; TRx: Total prescription data
Source: IQVIA Xponent, Weekly (ending 16 July 2021)
Novo NordiskⓇView entire presentation